Topiramate Reduces Headache Days in Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study

This study investigated the effectiveness of topiramate for chronic migraine prevention. Chronic migraine affects many individuals and causes significant disability. Preventive treatments are crucial, but data on these treatments are limited. Topiramate is already approved for preventing migraine headaches in adults. In this trial, patients aged 18-65 with chronic migraines were included. Patients had to experience at least 15 migraine days monthly for three months. They were randomly assigned to receive either topiramate or a placebo for 16 weeks. Topiramate was dosed flexibly based on patient needs, with a target of 100 mg daily. The study found that topiramate reduced migraine days by 3.5 days monthly. Most patients reported treatment-related adverse effects, with 75% in the topiramate group. Common side effects included paraesthesia and nausea. Overall, the trial showed topiramate is effective and tolerable for chronic migraine. Clinical relevance: This research indicates that topiramate effectively reduces migraine days for patients.